SGLT2抑制剂降低糖尿病患者心血管风险的研究进展  

Research progress of SGLT2 inhibitors for reduction of cardiovascular risk in patients with diabetes

作　　者：安秀敏[1] 缪珩[1] 

机构地区：[1]南京医科大学第二附属医院内分泌科,210000

出　　处：《国际内分泌代谢杂志》2017年第4期250-253,共4页International Journal of Endocrinology and Metabolism

摘　　要：Na^＋-葡萄糖协同转运蛋白（SGLT）2抑制剂是一类新型降糖药物，通过抑制肾脏近端小管SGLT2对葡萄糖的重吸收而降低血糖。EMPA—REG OUTCOME试验表明，恩格列净可降低合并高危心血管风险的糖尿病患者的主要不良心血管事件。SGLT2抑制剂可能通过降低血压、降低血容量、促进钠盐排出、对肾脏血流动力学的改善、减轻体重、增加胰岛素敏感性、抑制心肌重构、降低尿酸等发挥其心血管保护作用，但其确切机制目前仍未明确。Sodium-glucose cotransporter （SGLT）2 inhibitors are a class of novel antidiabetic drugs, which can reduce plasma glucose through inhibiting SGLT2-mediated glucose reabsorption in the proximal tubule of kidney. EMPA-REG OUTCOME trail shows that empagliflozin can reduce the major adverse cardiovascular events of diabetics with high cardiovascular risks. The potential mechanism of cardiovascular protective effects of SGLT2 inhibitors maybe include decrease of blood pressure, reduction of plasma volume, depletion of sodium, beneficial effects on renal hemodynamics, weight loss, improvement of insulin-sensitivity, inhibition on myocardial remodeling, decrease of uric acid, etc, but the exact mechanism still remains unclear.

关 键 词：SGLT2抑制剂 心血管风险 糖尿病 恩格列净 

分 类 号：R587.2[医药卫生—内分泌]